Circulating cell-free DNA (cfDNA) has been shown to have potential as a non-invasive substrate for the detection and monitoring of tumor cells. As circulating tumor DNA is often present at low frequencies within cfDNA, targeted sequencing is an optimal tool for mutation detection. However, some commercially available cfDNA isolation kits can be difficult to implement.
Advances in next-generation sequencing (NGS) technology has enabled the use of cfDNA as a biomarker for liquid biopsy research applications.
Download this application note to discover: